Middle East & Africa Plasmid Dna Contract Manufacturing Market Size & Outlook
Middle East & Africa plasmid dna contract manufacturing market, 2018-2030 (US$M)
Related Markets
MEA plasmid dna contract manufacturing market highlights
- The MEA plasmid dna contract manufacturing market generated a revenue of USD 12.2 million in 2023.
- The market is expected to grow at a CAGR of 19.1% from 2024 to 2030.
- In terms of segment, cell & gene therapy was the largest revenue generating application in 2023.
- Cell & Gene Therapy is the most lucrative application segment registering the fastest growth during the forecast period.
- Country-wise, UAE is expected to register the highest CAGR from 2024 to 2030.
MEA data book summary
| Market revenue in 2023 | USD 12.2 million |
| Market revenue in 2030 | USD 41.4 million |
| Growth rate | 19.1% (CAGR from 2023 to 2030) |
| Largest segment | Cell & gene therapy |
| Fastest growing segment | Cell & Gene Therapy |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Cell & Gene Therapy, Immunotherapy |
| Key market players worldwide | Charles River Laboratories International Inc, Boehringer Ingelheim, Thermo Fisher Scientific Inc, Lonza Group Ltd, Viva Biotech, VGXI, PlasmidFactory, BioCina, TriLink BioTechnologies, Esco Aster |
Other key industry trends
- In terms of revenue, MEA region accounted for 3.7% of the global plasmid dna contract manufacturing market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 203.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Plasmid DNA Contract Manufacturing Market Scope
Plasmid DNA Contract Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Middle East & Africa plasmid dna contract manufacturing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to plasmid dna contract manufacturing market will help companies and investors design strategic landscapes.
Cell & gene therapy was the largest segment with a revenue share of 59.84% in 2023. Horizon Databook has segmented the Middle East & Africa plasmid dna contract manufacturing market based on cell & gene therapy, immunotherapy covering the revenue growth of each sub-segment from 2018 to 2030.
The growing popularity of gene therapy, rising burden of cancer cases, and heavy investments on technology & innovations are the factors driving the market in the region. For instance, according to a report by Swedish Institute for Health Economics (IHE) titled Cancer Care in the Middle East and Africa, the annual incidence of newly diagnosed cancer cases per 100,000 people has increased since the year 2000.
Risk factors such as smoking and obesity are on the rise, along with changes in demographics. The number of newly diagnosed cancer cases could increase from 410,000 to 720,000 cases annually between 2020 and 2040 as a result of demographic changes.
Reasons to subscribe to Middle East & Africa plasmid dna contract manufacturing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Middle East & Africa plasmid dna contract manufacturing market databook
-
Our clientele includes a mix of plasmid dna contract manufacturing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa plasmid dna contract manufacturing market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa plasmid dna contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
MEA plasmid dna contract manufacturing market size, by country, 2018-2030 (US$M)
Middle East & Africa Plasmid DNA Contract Manufacturing Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
